Promising new treatments for neovascular age-related macular degeneration

Stephan Michels, Ursula Schmidt-Erfurth, Philip J. Rosenfeld

Research output: Contribution to journalReview articlepeer-review

65 Scopus citations


Angiogenesis, the growth of new blood vessels from existing blood vessels, is responsible for vision loss in a variety of ophthalmic diseases. In neovascular age-related macular degeneration (AMD), the leading cause for legal blindness in many industrialised countries, abnormal blood vessels grow in the macula and cause blindness. There are a number of factors important in the angiogenic cascade but VEGF-A has been implicated in recent years as the major factor responsible for neovascular and exudative diseases of the eye. Numerous antiangiogenic drugs are in development but anti-VEGF drugs have shown great promise in treating neovascular AMD and other ocular diseases, and many of these drugs have been adopted from oncology where antiangiogenic therapy is gaining wide acceptance. For the first time in neovascular AMD, anti-VEGF drugs have brought the hope of vision improvement to a significant proportion of patients. This review provides an overview on angiogenic mechanisms, potential antiangiogenic treatment strategies and different antiangiogenic drugs with special focus on neovascular AMD.

Original languageEnglish (US)
Pages (from-to)779-793
Number of pages15
JournalExpert opinion on investigational drugs
Issue number7
StatePublished - Jul 1 2006


  • Age-related macular degeneration
  • Angiogenesis
  • Neovascularisation
  • Vascular endothelial growth factor
  • Vascular permeability

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Promising new treatments for neovascular age-related macular degeneration'. Together they form a unique fingerprint.

Cite this